Dystrophin - Pipeline Review, H1 2020

February 2020 | 122 pages | ID: DBEF9AE823A2EN
Global Markets Direct

Abstracts

Dystrophin - Pipeline Review, H1 2020

SUMMARY

Dystrophin (DMD) pipeline Target constitutes close to 49 molecules. Out of which approximately 43 molecules are developed by companies and remaining by the universities/institutes. The latest report Dystrophin (DMD) - Pipeline Review, H1 2020, outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It act as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 5, 1, 24 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Musculoskeletal Disorders which include indications Duchenne Muscular Dystrophy and Muscular Dystrophy.

Furthermore, this report also reviews key players involved in Dystrophin (DMD) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD)
• The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects
• The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Dystrophin (DMD)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Dystrophin (DMD) - Overview
Dystrophin (DMD) - Therapeutics Development
Dystrophin (DMD) - Therapeutics Assessment
Dystrophin (DMD) - Companies Involved in Therapeutics Development
Dystrophin (DMD) - Drug Profiles
Dystrophin (DMD) - Dormant Products
Dystrophin (DMD) - Discontinued Products
Dystrophin (DMD) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Alpha Anomeric, H1 2020
Pipeline by Audentes Therapeutics Inc, H1 2020
Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Pipeline by Dystrogen Therapeutics SA, H1 2020
Pipeline by Editas Medicine Inc, H1 2020
Pipeline by Evox Therapeutics Ltd, H1 2020
Pipeline by FibroGenesis LLC, H1 2020
Pipeline by MyoGene Bio LLC, H1 2020
Pipeline by Nippon Shinyaku Co Ltd, H1 2020
Pipeline by NS Pharma Inc, H1 2020
Pipeline by OliPass Corporation, H1 2020
Pipeline by Pepgen Ltd, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Sarepta Therapeutics Inc, H1 2020
Pipeline by Sutura Therapeutics Ltd, H1 2020
Pipeline by Tolerion Inc, H1 2020
Pipeline by Vertex Pharmaceuticals Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Alpha Anomeric
Audentes Therapeutics Inc
Daiichi Sankyo Co Ltd
Dystrogen Therapeutics SA
Editas Medicine Inc
Evox Therapeutics Ltd
FibroGenesis LLC
MyoGene Bio LLC
Nippon Shinyaku Co Ltd
NS Pharma Inc
OliPass Corporation
Pepgen Ltd
Pfizer Inc
Sarepta Therapeutics Inc
Sutura Therapeutics Ltd
Tolerion Inc
Vertex Pharmaceuticals Inc